Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imatinib - Novartis

Drug Profile

Imatinib - Novartis

Alternative Names: CGP 57148; CGP 57148B; CTI 571; Gleevec; Glivec; Imatinib mesilate; Imatinib mesylate; QTI 571; Ruvise; STI 571

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Dermatofibrosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic mastocytosis
  • Phase II Acute myeloid leukaemia; Fibroma; Malignant melanoma; Non-Hodgkin's lymphoma; Prostate cancer
  • No development reported Mesothelioma
  • Discontinued Diffuse scleroderma; Glioblastoma; Non-small cell lung cancer; Polycythaemia vera; Pulmonary arterial hypertension; Sarcoma; Small cell lung cancer; Systemic scleroderma

Most Recent Events

  • 14 Feb 2019 Phase-I/II clinical trials in Gastrointestinal stromal tumours (Combination therapy, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in South Korea (PO) (NCT03609424)
  • 12 Nov 2018 Phase-II clinical trials in Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Czech Republic, Spain, USA (PO) (NCT03578367)
  • 28 Aug 2018 Novartis completes a phase I/II trial for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT00667953)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top